A Brexit Boost for German Pharma?


Research conducted by CPhI Worldwide, drawing from the CPhI Annual Report, ranks Germany as Europe’s preeminent pharma industry. 

According to the report’s Pharma Index, Germany finished ahead of its European rivals in API manufacturing, competitiveness, innovation, finished product manufacturing, and growth potential, thus “consolidating its status as an elite pharmaceutical market.”

One of the most notable trends, the report states, is the sudden rise in anticipated growth potential for Germany in 2019/2020, increasing by 11% from 2018. The research’s authors attribute the shifting European outlook over the last couple of years to wider macro changes, as well as the continued strength of European pharma. Germany is perceived to be reaping a “Brexit boost” in its medium-term growth potential – with an equal drop in the UK scores directly correlating to the increases seen in Germany’s. 

The full CPhI Pharma Market Index will be available later in the year as part of the CPhI 2019 Industry Report. This year’s CPhI Worldwide event will be held at Messe Frankfurt, Germany, November 5-7, 2019.



Related Videos
Jason Tate, FSP Talent Strategy Lead, PPD, part of Thermo Fisher Scientific
Related Content